FI106466B - Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi Download PDF

Info

Publication number
FI106466B
FI106466B FI932997A FI932997A FI106466B FI 106466 B FI106466 B FI 106466B FI 932997 A FI932997 A FI 932997A FI 932997 A FI932997 A FI 932997A FI 106466 B FI106466 B FI 106466B
Authority
FI
Finland
Prior art keywords
benzyloxy
difluoro
amino
phenyl
ethyl acetate
Prior art date
Application number
FI932997A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932997A0 (fi
FI932997A (fi
Inventor
Daniel Schirlin
Celine Tarnus
Dorsselaer Viviane Van
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI932997A0 publication Critical patent/FI932997A0/fi
Publication of FI932997A publication Critical patent/FI932997A/fi
Application granted granted Critical
Publication of FI106466B publication Critical patent/FI106466B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
FI932997A 1991-01-02 1993-06-29 Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi FI106466B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP91400005 1991-01-02
EP91400005 1991-01-02
US9109741 1991-12-20
PCT/US1991/009741 WO1992012123A1 (fr) 1991-01-02 1991-12-20 Composes antiviraux
US78809897 1997-01-23
US08/788,098 US5716973A (en) 1991-01-02 1997-01-23 Anti-viral compounds

Publications (3)

Publication Number Publication Date
FI932997A0 FI932997A0 (fi) 1993-06-29
FI932997A FI932997A (fi) 1993-06-29
FI106466B true FI106466B (fi) 2001-02-15

Family

ID=26129945

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932997A FI106466B (fi) 1991-01-02 1993-06-29 Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi

Country Status (19)

Country Link
US (1) US5716973A (fr)
EP (1) EP0565631B1 (fr)
JP (1) JP3198416B2 (fr)
AT (1) ATE143025T1 (fr)
AU (1) AU649766B2 (fr)
CA (1) CA2098020C (fr)
DE (1) DE69122266T2 (fr)
DK (1) DK0565631T3 (fr)
ES (1) ES2094344T3 (fr)
FI (1) FI106466B (fr)
GR (1) GR3021988T3 (fr)
HU (1) HU210647B (fr)
IE (1) IE75381B1 (fr)
IL (1) IL100477A (fr)
NO (1) NO180334C (fr)
NZ (1) NZ241099A (fr)
PT (1) PT99961B (fr)
WO (1) WO1992012123A1 (fr)
ZA (1) ZA9110141B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253050T1 (de) 1992-03-11 2003-11-15 Narhex Ltd Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
EP0633881B1 (fr) * 1992-03-11 2003-10-29 Narhex Limited Derives amines d'hydrocarbures a substitution oxo et hydroxy
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
GB9303518D0 (en) * 1993-02-22 1993-04-07 Merrell Dow Pharma Combinations of retroviral inhibitors
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
CA2166693C (fr) * 1993-07-08 1999-08-24 Daniel Schirlin Analogues de statone difluores
CN1130898A (zh) * 1993-09-09 1996-09-11 默里尔药物公司 二氟斯特酮抗病毒类似物
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
CA2182476C (fr) * 1994-02-04 2000-12-26 Robert A. Farr Derives de difluorostatone macrocyclique utiles en tant qu'agents antiviraux
MX9700414A (es) * 1994-07-15 1998-05-31 Merrell Pharma Inc Agentes antivirales de difluoroestatona.
US6114380A (en) * 1995-12-18 2000-09-05 Merrell Pharmaceuticals Inc. Difluoro statone analogs
JP4711621B2 (ja) 2001-06-12 2011-06-29 ウェルスタット セラピューティクス コーポレイション 代謝障害治療用化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171103A (en) * 1966-03-24 1969-11-19 Gas Council Hydrogenation of Hydrocarbons.
CH672792A5 (fr) * 1985-02-19 1989-12-29 Sandoz Ag
US5066643A (en) * 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
DE3674131D1 (de) * 1985-04-19 1990-10-18 Upjohn Co Substituierte dihalo-statin-reninhemmungsmittel.
GB8619182D0 (en) * 1986-08-06 1986-09-17 Sandoz Ltd Peptides & derivatives
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
FR2614533A1 (fr) * 1987-04-23 1988-11-04 Sandoz Sa Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
FR2624513A1 (fr) * 1987-12-15 1989-06-16 Sandoz Sa Peptides contenant du silicium, leur preparation et leur utilisation comme medicaments
IL90872A0 (en) * 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
JPH03505875A (ja) * 1988-07-08 1991-12-19 スミスクライン・ベックマン・コーポレイション レトロウイルス・プロテアーゼ結合ペプチド
CA2010531A1 (fr) * 1989-03-06 1990-09-06 Werner Neidhart Derives d'acides amines
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5559140A (en) * 1991-01-02 1996-09-24 Merrell Pharmaceuticals Inc. Difluoro statone analogs
HU9402744D0 (en) * 1992-03-25 1994-12-28 Pfizer Ltd Antiviral peptides
EP1447398A1 (fr) * 1992-05-21 2004-08-18 Monsanto Company Inhibiteurs de protéase rétrovirale

Also Published As

Publication number Publication date
AU649766B2 (en) 1994-06-02
DE69122266T2 (de) 1997-03-27
HU210647B (en) 1995-06-28
NO180334B (no) 1996-12-23
ZA9110141B (en) 1992-10-28
PT99961B (pt) 1999-06-30
NO180334C (no) 1997-04-02
NO932377L (no) 1993-06-29
JP3198416B2 (ja) 2001-08-13
GR3021988T3 (en) 1997-03-31
US5716973A (en) 1998-02-10
FI932997A0 (fi) 1993-06-29
CA2098020A1 (fr) 1992-07-03
HU9301918D0 (en) 1993-12-28
NO932377D0 (no) 1993-06-29
CA2098020C (fr) 2003-10-21
IE914580A1 (en) 1992-07-15
ATE143025T1 (de) 1996-10-15
HUT65739A (en) 1994-07-28
EP0565631B1 (fr) 1996-09-18
EP0565631A1 (fr) 1993-10-20
ES2094344T3 (es) 1997-01-16
PT99961A (pt) 1993-01-29
WO1992012123A1 (fr) 1992-07-23
IE75381B1 (en) 1997-09-10
DE69122266D1 (de) 1996-10-24
JPH07502255A (ja) 1995-03-09
AU9179091A (en) 1992-08-17
DK0565631T3 (da) 1996-10-07
IL100477A (en) 1996-07-23
NZ241099A (en) 1994-08-26
FI932997A (fi) 1993-06-29

Similar Documents

Publication Publication Date Title
FI106466B (fi) Menetelmä terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi
EP0337714A3 (fr) Inhibiteurs de la protéase du HIV pour le traitement du SIDA
JPH0741497A (ja) レトロ等立体性ジペプチド、その製造方法及び薬剤におけるレニン阻害剤としてのその使用
AU672867B2 (en) 4-amino-3-hydroxycarboxylic acid and their use as anitvirals
US5559140A (en) Difluoro statone analogs
FI120389B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten difluoristatonianalogien valmistamiseksi
AU683927B2 (en) Difluoro statone antiviral analogs
KR100367379B1 (ko) 항바이러스제로유용한마크로시클릭디플루오로스타톤유도체
US6114380A (en) Difluoro statone analogs

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS INC.

Free format text: AVENTIS INC.